Potent, durable, and redosable non-viral genetic medicines
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
What they do:
Building programmable therapeutics for the immune system
Quick facts:
HQ: San Francisco, CA, United States
What they do:
Adventris makes cancer vaccines
Quick facts:
HQ: Baltimore, MD, United States
What they do:
Elevated mRNA for transformative medicines.
Quick facts:
HQ: San Francisco, CA, United States
What they do:
Breakthrough medicines unlocking the biology of heme
Quick facts:
HQ: San Francisco, CA, United States
What they do:
Next-generation biocides for sustainable agriculture at scale
Quick facts:
HQ: New York, NY, United States
What they do:
Altay develops disease-modifying therapies targeting transcription…
Quick facts:
HQ: San Francisco, CA, United States
Funding:
$15.7M · Equity · Oct 2026
Potent, durable, and redosable non-viral genetic medicines
San Francisco, CA, United States
10 employees, according to the company profile.
There are no funding rounds for Engage Bio in our data.
Similar startups: Granza Bio, Adventris Pharmaceuticals, and ParcelBio.